Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
A nineteen year old patient received a one milliliter dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of overdose in a 19-year-old patient who received HBV (Engerix B) for prophylaxis. In MAY-2025, the patient received the 1st dose of Engerix B. In MAY-2025, an unknown time after receiving Engerix B, the patient experienced overdose (Verbatim: A nineteen year old patient received a one milliliter dose). The outcome of the overdose was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-JUN-2025 Registered Nurse called to ask what to do in this case regarding a patient's Engerix B schedule. A nineteen-year-old patient received a one milliliter dose last May 2025, which led to overdose. On the day before reporting on 17-JUN-2025, patient received a zero point five milliliter dose. The reporter asked for advise. Vaccination date was obtained in the call (no specific day of administration mentioned by the Registered Nurse's end for first dose). No vaccine detail and no patient demographics were obtained in the call. No further information was obtained in the call.